日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis

撤稿声明：BICC1通过诱导不依赖于VEGF的血管生成来驱动胰腺癌进展。

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02561-9
Huang, Chongbiao; Li, Hui; Xu, Yang; Xu, Chao; Sun, Huizhi; Li, Zengxun; Ge, Yi; Wang, Hongwei; Zhao, Tiansuo; Gao, Song; Wang, Xiuchao; Yang, Shengyu; Sun, Peiqing; Liu, Zhe; Liu, Jing; Chang, Antao; Hao, Jihui
血管生成
胰腺癌
VEGF
肿瘤
EGF
肿瘤免疫
发表日期：2026
文献求助 收藏

Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer

靶向损伤相关巨噬细胞中的GPR34可增强抗肿瘤免疫力并提高苏鲁替尼在胰腺癌中的疗效

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-026-02641-4
Guo, Xiaofan; Liu, Yuxiao; Li, Tianchen; An, Xiaopeng; Song, Yuning; Xu, Peijun; Huang, Jing; Zou, Yiping; Xu, Bohang; Xie, Yongjie; Li, Zekun; Meng, Chenyang; Zhao, Tiansuo; Wang, Xiuchao; Wang, Hongwei; Gao, Chuntao; Zhou, Xuan; Yu, Jun; Gao, Song; Hao, Jihui
胰腺癌
免疫/内分泌
细胞生物学
巨噬细胞
巨噬细胞
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial

围手术期替雷利珠单抗联合乐伐替尼治疗复发风险高的可切除肝细胞癌：单臂 II 期试验

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-68108-2
Chen, Lu; Zhai, Shujie; Liu, Yayue; Gong, Wenchen; Fang, Feng; Wu, Qiang; Cui, Yunlong; Zhang, Wei; Li, Huikai; Li, Yongmei; Hao, Jihui; Song, Tianqiang
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial

在中国晚期胰腺腺癌患者中，NALIRIFOX 对比吉西他滨联合白蛋白紫杉醇：一项随机、开放标签的 II 期试验

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-026-68409-0
Gao, Chuntao; Zhang, Yanqiao; Qu, Xiujuan; Chen, Xingyun; Zhang, Jingdong; Wu, Heshui; Sun, Meili; Zha, Yong; Wang, Junbin; Wang, Yusheng; Li, Zhihua; Gao, Jinghua; Lin, Rongbo; Zang, Aimin; Zhang, Huiqing; Yuan, Xianglin; Du, Chengyou; Zhao, Jun; Yang, Yongsheng; Shi, Xuetao; Cheng, Wei; Wang, Bangmao; Wu, Shikai; Zhao, Tiansuo; Wang, Jian; Gao, Song; Wang, Xiuchao; Ma, Weidong; Liu, Rui; Shi, Yehui; Liu, Yanping; Xie, Yijiao; Niu, Miao; Zhao, Fuchen; Yu, Jun; Hao, Jihui
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

AI-Guided SERS Defines a Pan-Cancer Diagnostic Biomarker

AI引导的SERS技术定义了一种泛癌诊断生物标志物

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202516268
Zhang, Cai; Zhao, Wen-Hui; Zuo, Duo; Zhou, Tianxing; Hou, Wenjing; Wang, Lingwei; Shi, Shangheng; Yang, Yang; Liu, Yuanyuan; Sun, Shao-Kai; Ren, Li; Ye, Zhaoxiang; Liu, Dingbin; Li, Dong; Chen, Xiaoyuan; Hao, Jihui
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells

肿瘤来源的白细胞介素35通过激活胰腺星状细胞促进胰腺癌肿瘤微环境中的纤维化

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202509074
Li, Hui; Sun, Huizhi; Liu, Jing; Wu, Yan; Wei, Lin; Li, Jianming; Yuan, Yudong; Xie, Peng; Xu, Chao; Luo, Guolu; Guan, Yuqi; Feng, Yukuan; Chang, Antao; Hao, Jihui; Huang, Chongbiao
肿瘤
肿瘤免疫
细胞生物学
胰腺癌
肿瘤微环境
发表日期：2026
文献求助 收藏

Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study

胰腺导管腺癌预后及CA19-9阻断的病理组学特征：一项真实世界多中心研究

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202515952
Chen, Qiangda; Xu, Zhihang; Zou, Yiping; Jiang, Zhenlai; Li, Yecheng; He, Taochen; Yin, Hanlin; Li, Jiali; An, Yanfei; Han, Jiande; Xie, Yuqi; Gan, Wei; Xu, Yaolin; Wang, Wenquan; He, Junyi; Wang, Haibo; Wu, Wenchuan; Ye, Zhenyu; Lou, Wenhui; Hao, Jihui; Liu, Liang; Yu, Jun; Pu, Ning
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione-Mediated Stemness Maintenance

线粒体钙单向转运蛋白通过谷胱甘肽介导的干性维持驱动胰腺癌的化疗耐药性

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202507346
Li, Zekun; Meng, Chenyang; Shen, Guangcong; Shan, Yueying; Wang, Junjin; Abudukeremu, Diliyaer; Zhao, Rui; Ni, Bo; Xu, Chao; Guo, Xiaofan; Yu, Jun; Wang, Kaiyuan; Yang, Shengyu; Li, YunZhan; Xie, Yongjie; Zhou, Tianxing; Hao, Jihui; Wang, Xiuchao
胰腺癌
肿瘤
线粒体
肿瘤免疫
发表日期：2026
文献求助 收藏

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study

IBI389（一种抗Claudin18.2×CD3双特异性抗体）在实体瘤和胃或胃食管肿瘤患者中的安全性和初步疗效结果：一项1期剂量递增和扩展研究

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-04597-8
Li, Xiaoyu; Dai, Ruihong; Xu, Qi; Guo, Zengqing; Hu, Changlu; Sun, Yuping; Niu, Zuoxing; Hao, Jihui; Zhang, Mingjun; Dai, Guanghai; Hua, Dong; Pan, Yueyin; Wang, Xin; Wei, Shuqing; Chen, Xiaobing; Wu, Qian; Zhang, Yulong; Zhou, Hui; Ying, Jieer; Zheng, Li; Bi, Feng
CD3
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy

基于理性分析和计算机模拟指导的APOBEC3F靶向CBE用于增强PDAC基因治疗

期刊:Communications Biology
影响因子:5.1
doi:10.1038/s42003-026-09770-0
Fang, Qingxiao; Zhang, Jin; Wang, Keshan; Wang, Zhe; Lv, Zongjing; Zhang, Xiaoping; Bi, Changhao; Zhang, Xueli; Yu, Jun; Feng, Yukuan; Zhou, Tianxing; Hao, Jihui; Yang, Chao
基因治疗
APOB
发表日期：2026
文献求助 收藏